Revolution Medicines is a clinical-stage biotechnology company focused on discovering and developing small molecule therapies that target key drivers of cancer growth. The company employs structure-based drug design, advanced proteomics and proprietary chemistry platforms to create novel inhibitors directed at RAS proteins and related signaling pathways. Its lead drug candidates include RMC-4630, an allosteric SHP2 inhibitor designed to overcome adaptive resistance in RAS- and RTK-driven tumors, and RMC-6236, a first-in-class RAS multi-specific inhibitor targeting multiple oncogenic RAS mutants.
Since its founding in 2015, Revolution Medicines has built a diverse pipeline addressing a range of solid tumors characterized by dysregulated RAS signaling. The company’s R&D programs span preclinical and clinical stages, with ongoing Phase 1 and Phase 2 trials evaluating monotherapy and combination regimens in patients with non-small cell lung cancer, colorectal cancer, pancreatic cancer and other advanced solid tumors. Revolution Medicines also collaborates with partners in North America and Europe to advance late-stage development and expand access to potential therapies for patients worldwide.
Headquartered in Redwood City, California, Revolution Medicines draws on a leadership team with deep expertise in oncology drug discovery, development and commercialization. Under the direction of President and Chief Executive Officer Mark J. Pykett, the senior management group has steered the company through its initial public offering and subsequent growth phases. The company maintains state-of-the-art research facilities in the San Francisco Bay Area, with additional scientific and clinical affairs staff supporting global trial operations.
Throughout its history, Revolution Medicines has raised capital through private financing rounds and a public listing on the Nasdaq exchange to fuel its research programs. The company continues to apply its integrated discovery engine to identify next-generation small molecules aimed at overcoming resistance mechanisms in cancer, with the goal of bringing novel, precision oncology treatments to patients in need.
AI Generated. May Contain Errors.
